At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 99 enrolled
Drug / intervention
ombitasvir/paritaprevir/ritonavir and dasabuvir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)
In Brief
A Phase 3 clinical trial evaluating ombitasvir/paritaprevir/ritonavir and dasabuvir and Ribavirin for Chronic Hepatitis C and 2 related conditions. Completed, enrolled 99 participants.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in US veterans with genotype 1 chronic hepatitis C virus infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C, Cirrhosis, Hepatitis C Virus
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartMay 2015
Primary CompletionAug 2016
Study CompletionOct 2016
TodayJul 2026
First PostedMay 13, 2015
Enrollment StartMay 13, 2015
Primary CompletionAug 22, 2016
Study CompletionOct 31, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.1 years ago
Interventions
ombitasvir/paritaprevir/ritonavir and dasabuvirdrug
Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
Ribavirindrug
Tablet